




How Does Science Work with Dementia Research?

• We have a variety of things to figure out: what actually causes AD (not just associated with it but really causes it)? If people with symptoms have irreversible damage to their brains, how can we identify people without symptoms who are at risk of developing AD? If we do studies on people without AD who are at risk, it could take decades to know what works and what does not, and what do we do in the meantime? Who funds the research and what side benefits might they get from raising hopes? Are drugs/treatments the only thing researchers work on?










Global Pandemic


- New case about every 4.1 seconds worldwide
- >60% people living with dementia are in low/middle income countries
- Western Europe/the Americas-peak incidence age 80-89, Asia 75-84, Africa 70-79
- Studies demonstrate worldwide caregiver struggles: time spent caregiving and not doing other activities, emotional strain with more anxiety and depression, economic strain with costs of care + needing to work less to provide care


Epidemiology & Impact of Dementia, Current State & Future Trends. World Health Organization 2015





















Gene research (NIA)


- Finding genes that are associated with increased or decreased risk of AD
- Understanding the actual function of those genes
- Look for genetic subtypes of disease to work toward targeted clinical trials
- Understand AD and ARD across diverse groups of people


AD Sequencing Project: >345 scientists from >62 institutions globally: to capture as much information as possible about genetic component <u>Alzheimer's Disease Sequencing Project</u> <u>Consortia | National Institute on Aging (nih.gov)</u>












Cholinesterase inhibitors-Donepezil (1996), Rivastigmine (2000) Galantamine(2001), increase cholinergic levels in brain, as we think degradation of acetylcholine contributes to neuronal damage in AD


Usually offered in mild to moderate AD

Unlikely to change trajectory of disease, might help some with symptoms


Most data is in Alzheimer dementia, but sometimes used in other forms of dementia


K Sharma, Molecular Medicine Reports June 11, 2019













Should people take lecanemab?


• Perhaps something to consider for people with MCI/very early dementia who can understand and agree to all the risks, who can afford the cost, and who have access to the infusion center every 2 weeks (we don't know yet how long people need treatment-indefinitely?) and have access to the ongoing PET scans and/or MRIs and/or lumbar punctures needed to get the treatment.








- 2023 meeting of Basic Cardiovascular Sciences Scientific Sessions-abstract presented by group from Tokyo about vaccine tested in mice that targets cells expressing senescence-associated glycoprotein (SAGP)
- Reduced amyloid deposits and reduced some inflammatory markers
- The mice who received the vaccine appeared to do better than those not vaccinated (placebo)
- <u>https://newsroom-heart.org</u> (abstract P3004)





















































WORLD ALZHEIMER REPORT 2020

•"Design, dignity, dementia: Dementia-related design and the built environment"

•"global perspective of dementia-related design that takes a cross cultural approach, reflects regional and economic differences in low-, middle- and high-income countries and considers urban versus rural settings"

•alzint.org

